( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

A new study has found that adults with newly diagnosed sciatica who received chiropractic spinal manipulation (CSM) were significantly less likely to experience opioid-related adverse drug events ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

The Food and Drug Administration approved a new type of nonopioid painkiller, Journaxv, or suzetrigine, drugmaker Vertex ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

Drug experts Drs. Volkow and McLellan set out a road map to reverse the opioid epidemic in 2016. Find out how we're doing now ...